As of 2025-12-31, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -0.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 117.66 mil USD. CHRS's TTM EBITDA according to its financial statements is -165.36 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 14.3x | 13.6x |
| Forward P/E multiples | 13.5x - 21.1x | 16.8x |
| Fair Price | (17.62) - 1.99 | (8.28) |
| Upside | -1349.8% - 40.9% | -687.3% |
| Date | EV/EBITDA |
| 2025-12-31 | -0.73 |
| 2025-12-30 | -0.71 |
| 2025-12-29 | -0.66 |
| 2025-12-26 | -0.65 |
| 2025-12-24 | -0.66 |
| 2025-12-23 | -0.65 |
| 2025-12-22 | -0.70 |
| 2025-12-19 | -0.67 |
| 2025-12-18 | -0.67 |
| 2025-12-17 | -0.67 |
| 2025-12-16 | -0.70 |
| 2025-12-15 | -0.70 |
| 2025-12-12 | -0.67 |
| 2025-12-11 | -0.73 |
| 2025-12-10 | -0.65 |
| 2025-12-09 | -0.62 |
| 2025-12-08 | -0.62 |
| 2025-12-05 | -0.56 |
| 2025-12-04 | -0.58 |
| 2025-12-03 | -0.57 |
| 2025-12-02 | -0.53 |
| 2025-12-01 | -0.61 |
| 2025-11-28 | -0.67 |
| 2025-11-26 | -0.64 |
| 2025-11-25 | -0.62 |
| 2025-11-24 | -0.62 |
| 2025-11-21 | -0.53 |
| 2025-11-20 | -0.48 |
| 2025-11-19 | -0.53 |
| 2025-11-18 | -0.57 |
| 2025-11-17 | -0.51 |
| 2025-11-14 | -0.55 |
| 2025-11-13 | -0.60 |
| 2025-11-12 | -0.67 |
| 2025-11-11 | -0.67 |
| 2025-11-10 | -0.60 |
| 2025-11-07 | -0.66 |
| 2025-11-06 | -0.77 |
| 2025-11-05 | -0.82 |
| 2025-11-04 | -0.81 |
| 2025-11-03 | -0.85 |
| 2025-10-31 | -0.91 |
| 2025-10-30 | -0.92 |
| 2025-10-29 | -0.95 |
| 2025-10-28 | -0.95 |
| 2025-10-27 | -0.85 |
| 2025-10-24 | -0.89 |
| 2025-10-23 | -0.90 |
| 2025-10-22 | -0.91 |
| 2025-10-21 | -0.95 |